CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Krystal Biotech, Inc.

KRYS
$10.17BLarge Cap

Next catalyst

Phase 3December 2026

KB803

Dystrophic Epidermolysis Bullosa

Get an email about KRYS's next catalysts

Track Krystal Biotech (KRYS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 3 more upcoming events in our data (Phase 2 readout).See the timeline

Catalyst Timeline

4 upcoming, 1 past

Phase 2

KB801 Phase 2 Est. Readout (EMERALD-1)

December 2026~KB80160

Primary completion for KB801 trial (NCT06999733) in Neurotrophic Keratitis

Source
Phase 3Next

KB803 Phase 3 Est. Readout (IOLITE)

December 2026~KB80316

Primary completion for KB803 trial (NCT07016750) in Dystrophic Epidermolysis Bullosa

Source
Phase 2

KB707 Phase 2 Est. Readout (KYANITE-1)

February 2027~KB707250

Primary completion for KB707 trial (NCT06228326) in Lung Cancer, Non-small Cell

Source
Phase 2

KB707 Phase 2 Est. Readout

July 2027~KB707240

Primary completion for KB707 trial (NCT05970497) in Cancer

Source

Market Overview

Stock performance and key metrics

NASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaPITTSBURGH275 employees
Drug Pipeline

Frequently asked questions

What is in Krystal Biotech, Inc.'s drug pipeline?→

CatalystAlert tracks 7 drug candidates in Krystal Biotech, Inc.'s (KRYS) pipeline across Phase 3, Phase 2. Its lead program is KB803 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Krystal Biotech, Inc.'s next FDA catalyst?→

Krystal Biotech, Inc.'s (KRYS) next tracked catalyst is a Phase 3 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track KRYS biotech catalysts?→

Add KRYS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Krystal Biotech, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply